12Apr 2021
Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial

Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial

Recurrent pericarditis (RP) incurs significant morbidity. Rilonacept inhibits both interleukin-1 alpha (IL-1α) and IL-1β; these cytokines are thought to play a major role in RP. This phase II study evaluated rilonacept efficacy and safety in RP.

  • #cardiology

Like

Save

Share